UK Companies House feature
TEVA UK HOLDCO 1 LIMITED
Profile
- Company number
- 12210932
- Status
- Active
- Incorporation
- 2019-09-17
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Subsidiaries
- Teva UK Holdco 2 Limited · 100% held · United Kingdom · Holding company
- Teva UK Holdco 3 Limited · 100% held · United Kingdom · Holding company
- Orvet UK · 100% held · United Kingdom · Holding company
- Teva Holdco US, Inc. · 100% held · United States · Holding company
- Anda Holdco Corp. · 100% held · United States · Holding company
- Anda Marketing, Inc. · 100% held · United States · Dormant company
- Anda Pharmaceuticals, Inc. · 100% held · United States · Wholesale distribution
- Anda, Inc. · 100% held · United States · Wholesale distribution
- Anda Puerto Rico Inc. · 100% held · Puerto Rico · Dormant company
- Teva API, Inc. · 100% held · United States · Manufacturer
- Teva Digital Health, Inc. · 100% held · United States · Development, Marketing
- Teva Pharmaceuticals USA, Inc. · 100% held · United States · Manufacturing, Distribution, Marketing
- Actavis Holdco US, Inc. · 100% held · United States · Holding company
- Actavis Laboratories UT, Inc. · 100% held · United States · Manufacturing
- Actavis Puerto Rico Holdings Inc. · 100% held · United States · Marketing, Holding company
- Coventry Acquisition, LLC · 100% held · United States · Holding company
- Actavis Pharma, Inc. · 100% held · United States · Holding company
- Actavis Pharmaceuticals NJ, Inc. · 100% held · United States · Manufacturing, R&D
- Watson Laboratories, Inc [Connecticut] · 100% held · United States · Manufacturing
- Watson Pharma Private Limited · 100% held · India · Development, Manufacturing, Commercial, Distribution
- Andrx LLC · 100% held · United States · Holding company
- Actavis Laboratories FL, Inc. · 100% held · United States · Manufacturing
- Watson Management Corporation · 100% held · United States · Marketing
- Watson Therapeutics, Inc. · 100% held · United States · Marketing
- Circa Pharmaceuticals West, Inc. · 100% held · United States · Dormant company
- Royce Research and Development Limited Partnership I · 100% held · United States · Dormant company
- Watson Laboratories, Inc. [Nevada] · 100% held · United States · Holding company, Marketing, Manufacturing
- Actavis US Holding LLC · 100% held · United States · Holding company
- Actavis LLC · 100% held · United States · Manufacturing, Holding company
- Actavis Elizabeth LLC · 100% held · United States · Manufacturing
- Actavis Kadian LLC · 100% held · United States · Holding company
- Actavis Mid Atlantic LLC · 100% held · United States · Marketing, Holding company
- Actavis South Atlantic LLC · 100% held · United States · Manufacturing, Marketing
- Actavis Totowa LLC · 100% held · United States · Marketing
- Cobalt Laboratories LLC · 100% held · United States · Holding company
- Watson Laboratories, LLC · 100% held · United States · Holding company
- Watson Manufacturing Services, Inc. · 100% held · United States · Marketing
- Watson Pharmaceuticals (Asia) Limited · 100% held · British Virgin Islands · Holding company
- Changzhou Siyao Pharmaceuticals Co., Ltd. · 25% held · China · Dormant company
- Watson Pharmaceuticals (China) Limited · 100% held · British Virgin Islands · Holding company
- Med All Enterprise Consulting (Shanghai) Co., Limited · 100% held · China · Investment
- WP Holdings, Ltd. · 100% held · British Virgin Islands · Holding company
- Watson Pharmaceuticals International, Limited · 100% held · British Virgin Islands · Holding company
- ANTARES PHARMA INC. · 1% held · United States · Strategic Investment
- Auspex Pharmaceuticals LLC · 100% held · United States · Marketing, Manufacturing, API
- Barr Pharmaceuticals, LLC · 100% held · United States · Holding company
- Barr Laboratories LLC · 100% held · United States · Manufacturing
- Barr International Services, Inc. · 100% held · United States · Holding company
- PLIVA, Inc. · 100% held · United States · Holding company
- Odyssey Pharmaceuticals, Inc. · 100% held · United States · Shelf finance company
- Teva Women's Health, LLC · 100% held · United States · Manufacturing, Marketing
- Teva Sales and Marketing, Inc. · 100% held · United States · Holding company, Marketing
- Cupric Holding Co. LLC · 100% held · United States · Holding company
- Cephalon, LLC · 100% held · United States · Holding company, Marketing
- Anesta LLC · 100% held · United States · Manufacturing
- Cephalon Development Corporation · 100% held · United States · Holding company
- Cephalon Clinical Partners, LP · 100% held · United States · Dormant company
- CIMA Labs, Inc. · 100% held · United States · Manufacturing
- East End Insurance, Ltd. · 100% held · Bermuda · Insurance
- Gecko Health Innovations, Inc. · 100% held · United States · Commercial, Investment, Manufacturing
- IVAX LLC · 100% held · United States · Holding company
- IVAX Pharmaceuticals Mexico, S.A. de C.V. · 100% held · Mexico · Distribution, Manufacturing, Marketing
- IVAX (Bermuda) Ltd. · 100% held · Bermuda · Holding company
- IVAX Argentina S.A. · 100% held · Argentina · Manufacturing, Marketing
- IVAX Far East, Inc. · 100% held · United States · Dormant company
- China National Pharmaceutical Logistics Corp. LTD · 10% held · China · Strategic Investment
- IVAX Holdings C.I. · 100% held · Cayman Islands · Holding company
- Laboratorio Chile, S.A. · 100% held · Chile · Manufactures, sells, markets and distributes medicines
- LBC International Corp. · 100% held · Cayman Islands · Dormant company
- Pharmatrade S.A. · 100% held · Chile · Commercial, Manufacturing
- Teva Pharmaceuticals Colombia SA S · 100% held · Colombia · Distribution, Manufacturing
- TEVA INVERSIONES Y EXPORTACIONES SPA · 100% held · Chile · Commercial, Marketing, Distribution
- IVAX Pharmaceuticals, LLC · 100% held · United States · Holding company, Marketing
- Doral Manufacturing, Inc. · 100% held · United States · Manufacturing
- Goldline Laboratories, Inc. · 100% held · United States · Marketing
- IVAX Pharmaceuticals NV, LLC · 100% held · United States · Holding company
- IVAX Pharmaceuticals Caribe, Inc. · 100% held · United States · Manufacturing
- IVAX Specialty Chemicals Sub, LLC · 100% held · United States · Holding company
- Maancirkel Holding B.V. · 100% held · Netherlands · Holding company
- Inmobiliaria Lemery, S.A. de C.V. · 100% held · Mexico · Commercial
- Patient Services and Solutions, Inc. · 100% held · United States · Holding company
- TAPI Puerto Rico, Inc. · 100% held · Puerto Rico · API, Manufacturing
- Teva Branded Pharmaceutical Products R&D LLC · 100% held · United States · Holding company
- Teva Neuroscience, Inc. · 100% held · United States · Marketing
- Teva Pharmaceuticals Panama, S.A. · 100% held · Panama · Commercial, Marketing
- Teva Respiratory, LLC · 100% held · United States · Manufacturing, Marketing
- IVAX Laboratories Puerto Rico, Inc. · 100% held · United States · Dormant company
- TEVA Uruguay S.A. · 100% held · Uruguay · Commercial, Distribution, Manufacturing
- Labrys Biologics, Inc. · 100% held · United States · R&D
- MicroDose Therapeutx, Inc. · 100% held · United States · Commercial, Investment, Manufacturing
- Sicor Inc. · 100% held · United States · Commercial, Manufacturing, Marketing
- Rakepoll Holding B.V. · 100% held · Netherlands · Holding company
- Lemery S.A. de C.V. · 100% held · Mexico · Manufacturing
- Sicor de México S.A. de C.V. · 100% held · Mexico · API, Manufacturing
- TEVA Pharmaceuticals Mexico S.A. de C.V. · 100% held · Mexico · Commercial
- UAB Teva Baltics · 100% held · Lithuania · Commercial, Manufacturing
- Teva Parenteral Medicines, Inc. · 100% held · United States · Manufacturing
- Teva Biopharmaceuticals USA, Inc. · 100% held · United States · R&D
- Teva Pharmaceutical Finance Company, LLC · 100% held · United States · Finance company
- Teva Pharmaceutical Finance IV, LLC · 100% held · United States · Finance company
- Teva Pharmaceutical Finance Netherlands III B.V. · 100% held · Netherlands · Finance company
- Teva Pharmaceutical Finance V, LLC · 100% held · United States · Dormant company
- Teva Pharmaceutical Finance VI, LLC · 100% held · United States · Dormant company
- Teton Pharmaceuticals, LLC · 100% held · United States · Licence holder
- GeminX Pharmaceuticals Canada, Inc. · 100% held · Canada · Dormant company
- Corporacion Medco CA · 100% held · Venezuela · Pharmaceutical Sales
- Schein Pharmaceuticals Bermuda Limited · 100% held · Bermuda · Pharmaceutical Sales
- Representaciones E Investigaciones Medicas SA · 0.009999999776482582% held · Mexico · Manufacturing
- Immobiliaria Leyfe, SA de C.V. · 0.009999999776482582% held · Mexico · Equipment Rental
- Inter Lab Pharmaceutica, SA de C.V. · 0.009999999776482582% held · Mexico · Manufacturing
- Watson Laboratories S. de R.L. de C.V. · 50% held · Mexico · Pharmaceutical Sales
- New Caribe CFC · 100% held · United States · Dormant company
- Teva API Services Mexico S de RL de C.V. · 50% held · Mexico · Outsourcing Services
Significant events
- “During March 2024, a loan receivable from a fellow group company of USD 900,000,000 with a maturity date of 24 March 2024 was extended to 24 March 2034, and loan payables to fellow group companies of USD 900,000,000 with a maturity date of 24 March 2024 were also extended to 24 March 2034.”
- “In June 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 1,101,893,094.26. The company then subscribed in cash for 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 1,101,893,094.26.”
- “As a result of the additional cash injection into the US subsidiaries, a fellow group company repaid USD 543,914,496 of the principal amount of USD 900,000,000 which was owed to Teva UK Holdco 3 Limited under the terms of a loan agreement dated March 2024. Teva UK Holdco 3 Limited used this cash sum to repay USD 543,914,496 of the loan note of USD 900,000,000 issued by Teva UK Holdco 3 Limited and held by the company, which otherwise had a redemption date of 24 March 2034. The company then used that amount to repay in full the loan note of USD 543,914,496 issued by the company and held by another fellow group company and which otherwise also had a redemption date of 24 March 2034. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “In August 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement the company allotted to the company's holding company, Teva Finance Holding B.V., 457,273,600 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 457,273,600. The company then subscribed in cash for 457,273,600 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 457,273,600. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “In December 2024 the company entered into a share exchange agreement with its ultimate parent company, Teva Pharmaceutical Industries Ltd and this had the effect on Teva UK Holdco 1 Limited as described below: Under the share exchange agreement, the company allotted one ordinary share of USD 1.00 credited as fully paid to Teva Pharmaceutical Industries Ltd, in exchange for a USD 1.00 on-demand interest-free receivable and one ordinary share of USD 1.00 in the capital of the company's direct subsidiary, Teva UK Holdco 2 Limited.”
- “During 2024, the group continued a restructuring of its US operations to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries, as described in the Strategic Report.”
- “In February 2025, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., 688,906,337 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 688,906,337. The company then subscribed in cash for 688,906,337 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 688,906,337. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “During June 2025, a loan receivable from a fellow group company of USD 958,654,252 with a maturity date of 24 June 2025 was extended to 25 June 2035, and loan payables to a fellow group company of USD 958,654,252 with a maturity date of 24 June 2025 was also extended to 25 June 2035.”
- “During July 2025, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., one ordinary share of USD 1.00 in the capital of the company at a cash subscription price of USD 602,295,285. The company then subscribed in cash for one ordinary share of USD 1.00 in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at a cash subscription price of USD 602,295,285. The amount of the premium at which each of those shares was allotted may be subject to adjustment under the terms of that agreement. As part of the agreement all intercompany balances arising on those transactions that affected the company were eliminated.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| COOPER, Dean Michael | Director | 2019-09-17 | Sep 1972 | British |
| KATZ, Yaron Aizik, Mr | Director | 2022-05-07 | Dec 1968 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HERMAN, Doron | Director | 2019-09-17 | 2022-05-07 |
| INNES, Kim | Director | 2019-09-17 | 2020-04-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-17 | Active |
Filing timeline
Last 20 of 33 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-01-21 | RP01SH01 | miscellaneous | legacy |
| 2025-10-06 | AA | accounts | accounts with accounts type full |
| 2025-09-29 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-08-14 | SH01 | capital | capital allotment shares |
| 2025-02-17 | SH01 | capital | capital allotment shares |
| 2025-01-30 | SH01 | capital | capital allotment shares |
| 2024-12-12 | RP04CS01 | confirmation-statement | second filing of confirmation statement with made up date |
| 2024-12-10 | SH01 | capital | capital allotment shares |
| 2024-10-21 | CS01 | confirmation-statement | confirmation statement |
| 2024-10-09 | AA | accounts | accounts with accounts type full |
| 2024-06-25 | SH01 | capital | capital allotment shares |
| 2023-12-14 | SH01 | capital | capital allotment shares |
| 2023-10-03 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-08-15 | AA | accounts | accounts with accounts type full |
| 2023-01-03 | AA | accounts | accounts with accounts type full |
| 2022-09-23 | CS01 | confirmation-statement | confirmation statement with updates |
| 2022-06-22 | SH01 | capital | capital allotment shares |
| 2022-05-09 | AP01 | officers | appoint person director company with name date |
| 2022-05-09 | TM01 | officers | termination director company with name termination date |
| 2021-11-12 | SH01 | capital | capital allotment shares |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.